Publications by authors named "Gerhard Held"

Claim this Profile
I
Integration of high-throughput proteomic data and complementary omics layers with PriOmics.
Robin Kosch, Katharina Limm, Annette M Staiger, Nadine S Kurz, Nicole Seifert, Gerhard Held

Genome Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
Christoph Röllig, Björn Steffen, Christoph Schliemann, Jan-Henrik Mikesch, Nael Alakel, Gerhard Held

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma.
Konstantinos Christofyllakis, Dominic Kaddu-Mulindwa, Vadim Lesan, Torben Rixecker, Igor Age Kos, Gerhard Held

Ann Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.
Moritz Bewarder, Konstantinos Christofyllakis, Milena Petersen, Gerhard Held, Sigrun Smola

Int J Mol Sci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.
Fabian Frontzek, Loïc Renaud, Ulrich Dührsen, Viola Poeschel, Sophie Bernard, Gerhard Held

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.
Ulrich Dührsen, Andreas Bockisch, Bernd Hertenstein, Imke E Karsten, Frank Kroschinsky, Gerhard Held

Blood Neoplasia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
Daniel Noerenberg, Franziska Briest, Cornelius Hennch, Kenichi Yoshida, Raphael Hablesreiter, Gerhard Held

J Clin Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-cell receptor reactivity against in nodular lymphocyte-predominant Hodgkin lymphoma.
Lorenz Thurner, Natalie Fadle, Evi Regitz, Sophie Roth, Onur Cetin, Gerhard Held

Haematologica· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.
Moritz Bewarder, Dominic Kaddu-Mulindwa, Igor Age Kos, Vadim Lesan, Gerhard Held

Haematologica· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience.
Julius C Enßle, Sebastian Wolf, Sebastian Scheich, Sarah Weber, Michael Kramer, Gerhard Held

Br J Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.
Catherine Thieblemont, Bettina Altmann, Fabian Frontzek, Loïc Renaud, Loic Chartier, Gerhard Held

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
Sabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, Mathias Hänel, Mar Tormo, Gerhard Held

Haematologica· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
Maher Hanoun, Leo Ruhnke, Michael Kramer, Christine Hanoun, Kerstin Schäfer-Eckart, Gerhard Held

J Cancer Res Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial.
Gerhard Held, Lorenz Thurner, Viola Poeschel, German Ott, Christian Schmidt

Hemasphere· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.
Lorenz Thurner, Marita Ziepert, Christian Berdel, Christian Schmidt, Peter Borchmann, Gerhard Held

Hemasphere· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The new German evidence-based guideline on diffuse large B-cell lymphoma-key aspects for radiation oncologists.
Michael Oertel, Christian Berdel, Gerhard Held, Klaus Herfarth, Heinz Schmidberger

Strahlenther Onkol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Dominic Kaddu-Mulindwa, Philipp Gödel, Nadine Kutsch, Jan-Michel Heger, Christof Scheid, Gerhard Held

Clin Lymphoma Myeloma Leuk· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Dominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, Stephan Stilgenbauer, Moritz Bewarder, Gerhard Held

Leuk Lymphoma· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma.
Roch Houot, Viola Poeschel, Bettina Altmann, Stephanie Angel, Lorenz Thurner, Gerhard Held

Hemasphere· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
Dominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, Marita Ziepert, Evi Regitz, Gerhard Held

Lancet Haematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Gerhard Held

Trials· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
Dominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, Stephanie Angel, Stephan Stilgenbauer

Eur J Nucl Med Mol Imaging· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma.
Carmen Nordmo, Gunther Glehr, Michael Altenbuchinger, Rainer Spang, Marita Ziepert, Gerhard Held

Leuk Lymphoma· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group).
Florian Zettl, Marita Ziepert, Bettina Altmann, Samira Zeynalova, Gerhard Held

Ann Hematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Fabian Frontzek, Marita Ziepert, Maike Nickelsen, Bettina Altmann, Bertram Glass, Gerhard Held

Lancet Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis